Table 5.
Multivariate analysis
| RI | NRM | LFS | OS | GRFS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Haplo vs MSD | 0.66 (0.52–0.83) | 0.0004 | 1.9 (1.43–2.53) | < 0.0001 | 0.96 (0.81–1.14) | 0.66 | 1.18 (0.96–1.43) | 0.11 | 0.93 (0.79–1.09) | 0.37 |
| Age (per 10 years) | 1.01 (0.94–1.08) | 0.87 | 1.33 (1.21–1.47) | < 0.0001 | 1.1 (1.05–1.17) | 0.0004 | 1.19 (1.12–1.27) | < 0.0001 | 1.11 (1.06–1.08) | < 0.0001 |
| Ph-neg B-ALL (ref) | ||||||||||
| Ph-pos B-ALL | 0.77 (0.63–0.95) | 0.012 | 1.15 (0.86–1.54) | 0.34 | 0.88 (0.75–1.14) | 0.12 | 0.74 (0.61–0.9) | 0.002 | 0.94 (0.82–1.08) | 0.4 |
| T-ALL | 1.04 (0.85–1.26) | 0.73 | 1.19 (0.87–1.62) | 0.28 | 1.07 (0.91–1.26) | 0.43 | 1.13 (0.94–1.36) | 0.19 | 1 (0.86–1.15) | 0.95 |
| CR2 vs CR1 | 2.5 (2.08–3) | < 0.0001 | 1.98 (1.5–2.62) | < 0.0001 | 2.31 (1.99–2.7) | < 0.0001 | 2.57 (2.17–3.06) | < 0.0001 | 1.95 (1.69–2.24) | < 0.001 |
| Year of HSCT | 0.99 (0.95–1.03) | 0.64 | 0.94 (0.89–1.01) | 0.074 | 0.98 (0.94–1.01) | 0.17 | 0.96 (0.92–1) | 0.082 | 1 (0.97–1.03) | 0.98 |
| Female to male vs. other | 0.96 (0.8–1.15) | 0.65 | 1.22 (0.94–1.57) | 0.14 | 1.03 (0.88–1.19) | 0.73 | 1.13 (0.95–1.34) | 0.16 | 1.27 (1.12–1.45) | 0.0002 |
| MAC TBI (reference) | ||||||||||
| MAC CT | 1.32 (1.08–1.61) | 0.006 | 1.03 (0.76–1.39) | 0.87 | 1.22 (1.04–1.44) | 0.016 | 1.1 (0.9–1.34) | 0.34 | 1.05 (0.9–1.23) | 0.54 |
| RIC | 1.61 (1.27–2.02) | < 0.0001 | 0.62 (0.43–0.88) | 0.007 | 1.18 (0.97–1.43) | 0.095 | 0.99 (0.79–1.24) | 0.92 | 1.02 (0.86–1.22) | 0.82 |
| Patient CMV positive | 0.96 (0.79–1.18) | 0.72 | 1.59 (1.15–2.19) | 0.005 | 1.12 (0.95–1.33) | 0.18 | 1.31 (1.07–1.6) | 0.009 | 1.13 (0.97–1.31) | 0.11 |
| Donor CMV positive | 1.21 (1.99–1.49) | 0.063 | 0.86 (0.65–1.15) | 0.32 | 1.09 (0.92–1.29) | 0.3 | 1.01 (0.84–1.23) | 0.89 | 1.01 (0.87–1.16) | 0.94 |
| Center (frailty) | 0.32 | 0.031 | 0.31 | 0.064 | 0.007 | |||||
| Acute GVHD grade II–IV | Acute GVHD grade III–IV | Chronic GVHD | Extensive chronic GVHD | |||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Haplo vs MSD | 1.53 (1.23–1.9) | 0.0002 | 1.54 (1.1–2.15) | 0.011 | 0.94 (0.74–1.18) | 0.58 | 0.61 (0.43–0.88) | 0.007 |
| Age (per 10 years) | 1.03 (0.96–1.1) | 0.43 | 1.08 (0.97–1.2) | 0.15 | 1.11 (1.03–1.18) | 0.005 | 0.17 (1.06–1.29) | 0.002 |
| Ph-neg B-ALL (ref) | ||||||||
| Ph-pos B-ALL | 0.93 (0.76–1.114) | 0.49 | 1.15 (0.83–1.58) | 0.4 | 0.82 (0.67–0.99) | 0.041 | 1.03 (0.79–1.35) | 0.83 |
| T-ALL | 0.88 (0.71–1.09) | 0.24 | 0.94 (0.66–1.33) | 0.73 | 0.84 (0.69–1.04) | 0.11 | 0.99 (0.74–1.32) | 0.94 |
| CR2 vs CR1 | 1.11 (0.9–1.37) | 0.31 | 1.34 (0.97–1.84) | 0.078 | 1.25 (1–1.57) | 0.051 | 1.55 (1.13–2.13) | 0.006 |
| Year of HSCT | 0.96 (0.92–1) | 0.053 | 1 (0.93–1.07) | 0.96 | 0.96 (0.92–1) | 0.044 | 1.04 (0.98–1.1) | 0.23 |
| Female to male vs. other | 1.23 (1.02–1.47) | 0.028 | 1.36 (1.03–1.82) | 0.033 | 1.73 (1.46–2.05) | < 0.0001 | 1.98 (1.57–2.5) | < 0.0001 |
| MAC TBI (reference) | ||||||||
| MAC CT | 0.82 (0.65–1.04) | 0.1 | 1.25 (0.9–1.75) | 0.19 | 0.78 (0.62–0.98) | 0.035 | 0.69 (0.49–0.96) | 0.03 |
| RIC | 0.78 (0.61–1.01) | 0.056 | 0.79 (0.53–1.19) | 0.26 | 0.81 (0.63–1.04) | 0.1 | 0.72 (0.5–1.04) | 0.078 |
| Patient CMV positive | 1.01 (0.82–1.25) | 0.93 | 1.34 (0.94–1.91) | 0.1 | 1.04 (0.85–1.27) | 0.69 | 1.17 (0.89–1.54) | 0.27 |
| Donor CMV positive | 1.04 (0.85–1.28) | 0.69 | 0.78 (0.56–1.08) | 0.13 | 1.05 (0.86–1.27) | 0.63 | 1.01 (0.77–1.31) | 0.97 |
| Center (frailty) | < 0.0001 | 0.1 | < 0.0001 | < 0.0001 | ||||
RI, relapse incidence; NRM, non-relapse mortality; LFS, leukemia-free survival; OS, overall survival; GVHD, graft versus host disease; GRFS, GVHD-free/relapse-free survival; MRD, minimal residual disease; ATG, anti-thymocyte globulin; PTCy, post-transplant cyclophosphamide; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; PB, peripheral blood; BM, bone marrow